Natixis’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History

Natixis’s Portfolio ONCE Stock Details ONCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-48,956	Closed	-$4.75M	–	1008
2019 Q3	$4.75M	Sell	48,956 -54,709	-53%	-$5.48M	0.03%	361
2019 Q2	$10.6M	Buy	+103,665	New	+$11.2M	0.08%	218
2019 Q1	–	Sell	-27,715	Closed	-$1.08M	–	923
2018 Q4	$1.08M	Buy	27,715 +14,481	+109%	+$628K	0.01%	502
2018 Q3	$721K	Sell	13,234 -831	-6%	-$56.8K	﹤0.01%	595
2018 Q2	$1.16M	Sell	14,065 -255	-2%	-$19.7K	0.01%	585
2018 Q1	$954K	Sell	14,320 -3,483	-20%	-$201K	0.01%	594
2017 Q4	$916K	Buy	+17,803	New	+$1.28M	0.01%	512

Natixis's ONCE Position: Q4 2019 in Review

Natixis sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 48,956 shares — an estimated $4.75M sold.

Natixis first reported a position in ONCE in Q4 2017 and held it in 7 quarters. The position peaked at $10.6M in Q2 2019. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.

Natixis reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
Natixis sold 48,956 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $4.75M.
Natixis first reported a position in Spark Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
Natixis's Spark Therapeutics, Inc. Common Stock position peaked at $10.6M in Q2 2019.
0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Natixis's 13F filing for Q4 2019, filed 14 Feb 2020.